These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


240 related items for PubMed ID: 1671782

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, Keske U, Hosten N, Mäurer J, Poewe W, Felix R.
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [Abstract] [Full Text] [Related]

  • 6. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ.
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K.
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [Abstract] [Full Text] [Related]

  • 9. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB, Bartenstein P, Schober O, Oberwittler C, Lerch H, Masur H.
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [Abstract] [Full Text] [Related]

  • 10. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W.
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G, Chierichetti F, Rossato A, Cagnin A, Fabbri M, Dam M, Ferlin G, Battistin L.
    J Neural Transm Suppl; 1995 Oct; 45():113-22. PubMed ID: 8748616
    [Abstract] [Full Text] [Related]

  • 17. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
    Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH.
    Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
    [Abstract] [Full Text] [Related]

  • 18. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [Abstract] [Full Text] [Related]

  • 19. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
    Berding G, Gratz KF, Kolbe H, Meyer GJ, Dengler R, Knoop BO, Hundeshagen H.
    Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
    [Abstract] [Full Text] [Related]

  • 20. [Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders].
    Pávics L, Dibó G, Ambrus E, Séra T, Vécsei L, Csernay L.
    Orv Hetil; 2000 May 14; 141(20):1073-7. PubMed ID: 10851890
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.